Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) just unveiled an announcement.
Shanghai Henlius Biotech, Inc. announced that its subsidiary, Henlius USA Inc., has received Orphan-drug Designation from the U.S. FDA for HLX43, an anti-PD-L1 antibody-drug conjugate, for the treatment of thymic epithelial tumors. This designation provides the company with benefits such as tax credits, fee exemptions, and market exclusivity, which could enhance its competitive positioning in the oncology market, particularly in the U.S., where no similar PD-L1 targeting ADCs have been approved.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$77.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, focusing on the development of innovative biologic drugs. The company specializes in antibody-drug conjugates and other therapies targeting advanced and metastatic solid tumors, with a market focus on oncology treatments.
Average Trading Volume: 1,453,409
Technical Sentiment Signal: Buy
Current Market Cap: HK$39.78B
See more insights into 2696 stock on TipRanks’ Stock Analysis page.